Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

October 2023

Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice

Rheumatol Ther. 2023;10(6):1503–1508 doi: 10.1007/s40744-023-00589-3

Fritz B,

In the UPJOINT open label study, the proportion of patients with PsA, and an inadequate response to csDMARDs or bDMARDs, who achieved minimal disease activity with upadacitinib was in line with the results of previous studies at 24 weeks. No new safety signals were identified.

Keywords:

June 2023

Baricitinib Improves Bone Properties and Biomechanics in Patients with Rheumatoid Arthritis – Results of the Prospective Interventional BARE BONE Trial

Arthritis Rheumatol. 2023 doi 10.1002/art.42617 Epub ahead of print

Simon D,

Bayat S,

The results from Simon, et al. show that baricitinib treatment correlates with improvements in bone stiffness. Further improvements were also observed at the end of Week 52, with an increase in estimated failure load and no measurable progression in bone erosion being reported.